WorthPointe’s Inspire Corporate Bond ETF IBD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.66M Sell
154,171
-52,796
-26% -$1.26M 0.92% 23
2026
Q1
$4.94M Sell
206,967
-105,329
-34% -$2.54M 1.34% 18
2025
Q4
$7.56M Buy
+312,296
New +$7.55M 1.99% 11
2024
Q1
Sell
-110,136
Closed -$2.6M 72
2023
Q4
$2.6M Buy
110,136
+69,041
+168% +$1.58M 1.32% 11
2023
Q3
$930K Buy
+41,095
New +$944K 0.55% 24

Other funds holding IBD

WorthPointe's IBD Position: Q2 2026 in Review

WorthPointe reduced its Inspire Corporate Bond ETF (IBD) stake by 26% in Q2 2026, selling an estimated $1.26M and leaving 154,171 shares worth $3.66M. The position accounts for 0.92% of the portfolio, ranked #23.

WorthPointe first reported a position in IBD in Q3 2023 and has held it in 5 quarters since. The position peaked at $7.56M in Q4 2025. 110 funds tracked by Wall St. Rank hold IBD as of Q2 2026.

  • WorthPointe held 154,171 shares of Inspire Corporate Bond ETF worth $3.66M as of Q2 2026.
  • WorthPointe sold 52,796 Inspire Corporate Bond ETF shares in Q2 2026, an estimated $1.26M.
  • Inspire Corporate Bond ETF made up 0.92% of WorthPointe's portfolio in Q2 2026, its #23 holding.
  • WorthPointe first reported a position in Inspire Corporate Bond ETF in Q3 2023 and has held it in 5 quarters since.
  • WorthPointe's Inspire Corporate Bond ETF position peaked at $7.56M in Q4 2025.
  • 110 funds tracked by Wall St. Rank held Inspire Corporate Bond ETF as of Q2 2026.

Based on WorthPointe's 13F filing for Q2 2026, filed 31 Jul 2026.